1. Home
  2. MGNX vs RVSB Comparison

MGNX vs RVSB Comparison

Compare MGNX & RVSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$2.95

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Logo Riverview Bancorp Inc

RVSB

Riverview Bancorp Inc

HOLD

Current Price

$5.07

Market Cap

108.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
RVSB
Founded
2000
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
108.9M
IPO Year
2013
1997

Fundamental Metrics

Financial Performance
Metric
MGNX
RVSB
Price
$2.95
$5.07
Analyst Decision
Hold
Buy
Analyst Count
5
1
Target Price
$3.40
$7.00
AVG Volume (30 Days)
1.3M
37.7K
Earning Date
06-15-2026
04-30-2026
Dividend Yield
N/A
1.55%
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
$149,500,000.00
N/A
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$9.82
P/E Ratio
N/A
$28.67
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$4.74
52 Week High
$3.50
$6.59

Technical Indicators

Market Signals
Indicator
MGNX
RVSB
Relative Strength Index (RSI) 67.59 33.29
Support Level $1.45 $5.03
Resistance Level $3.50 $5.19
Average True Range (ATR) 0.22 0.13
MACD 0.07 -0.04
Stochastic Oscillator 67.46 13.27

Price Performance

Historical Comparison
MGNX
RVSB

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About RVSB Riverview Bancorp Inc

Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.

Share on Social Networks: